EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Concordance between Three Homologous Recombination Deficiency (HRD) Assays in Patients with High-Grade Epithelial Ovarian Cancer

Elena Fountzilas, Kyriaki Papadopoulou, Thomas Chatzikonstantinou, Georgios Karakatsoulis iD, Pantelis Constantoulakis iD, Aikaterini Tsantikidi, Georgios Tsaousis iD, Sofia Karageorgopoulou, Anna Koumarianou iD, Davide Mauri, Anastasios Ntavatzikos iD, Zacharenia Saridaki iD und 4 weitere

Cancers · 22.11.2023 · 15 (23) · 5525

DOI: 10.3390/cancers15235525 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 22.11.2023. Verfasst von Elena Fountzilas und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, St. Lukes's Hospital, 55236 Thessaloniki, Greece. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca (Hellas), Hellenic Cooperative Oncology Group, AstraZeneca Hellas.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Our aim was to evaluate the concordance between the Myriad MyChoice and two alternative homologous recombination deficiency (HRD) assays (AmoyDx HRD Focus NGS Panel and OncoScan™) in patients with epithelial ovarian cancer (EOC). Tissue samples from 50 patients with newly diagnosed EOC and known Myriad MyChoice HRD status were included. DNA aliquots from tumor samples, previously evaluated with Myriad MyChoice and centrally reassessed, were distributed to laboratories to assess their HRD status using the two platforms, after being blinded for the Myriad MyChoice CDx HRD status. The primary endpoint was the concordance between Myriad MyChoice and each alternative assay. Tumor samples were evaluated with an AmoyDx® HRD Focus Panel (n = 50) and with OncoScan™ (n = 43). Both platforms provided results for all tumors. Analysis showed that correlation was high for the Myriad MyChoice GI score and AmoyDx® HRD Focus Panel (r = 0.79) or OncoScan™ (r = 0.87) (continuous variable). The overall percent agreement (OPA) between Myriad MyChoice GI status (categorical variable) and each alternative assay was 83.3% (68.6–93.3%) with AmoyDx and 77.5% (61.5–89.2%) with OncoScan™. The OPA in HRD status between Myriad MyChoice and AmoyDx was 88.6% (75.4–96.2). False-positive rates were 31.6% (6/19) for AmoyDx GI status and 31.9% (7/22) for OncoScan™, while false-negative rates were 0% (0/28, AmoyDx) and 11.1% (2/18, OncoScan™) compared with the Myriad MyChoice GI status. While substantial concordance between Myriad MyChoice and alternative assays was demonstrated, prospective validation of the analytical performance and clinical relevance of these assays is warranted.

Schlagwörter

Stichwörter der Autor:innen

biomarkerconcordanceenomic instabilityepithelial ovarian cancerhomologous recombination deficiency

Autor:innen und Institutionen

  • Department of Medical Oncology, St. Lukes's Hospital, 55236 Thessaloniki, Greece.
  • Medical Oncology, German Oncology Center, European University Cyprus, 1516 Nicosia, Cyprus.
  • Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, 54006 Thessaloniki, Greece.
  • Institute of Applied Biosciences, Centre for Research and Technology Hellas, 57001 Thessaloniki, Greece.
  • Genotypos M.S.A., 11528 Athens, Greece.
  • Genekor Medical S.A., 15344 Athens, Greece.

ORCID-Profile: Georgios Karakatsoulis, Pantelis Constantoulakis, Georgios Tsaousis, Anna Koumarianou, Anastasios Ntavatzikos, Zacharenia Saridaki, Georgios Petrakis, George Fountzilas, Michalis Liontos

Förderung

  • AstraZeneca (Hellas)
  • Hellenic Cooperative Oncology Group
  • AstraZeneca Hellas
  • Hellenic Society for Medical Oncology (HeSMO)

Zitieren

APA

Fountzilas, E., Papadopoulou, K., Chatzikonstantinou, T., Karakatsoulis, G., Constantoulakis, P., Tsantikidi, A., Tsaousis, G., Karageorgopoulou, S., Koumarianou, A., Mauri, D., Ntavatzikos, A., Saridaki, Z., Petrakis, G., Fostira, F., Fountzilas, G., & Liontos, M. (2023). Concordance between Three Homologous Recombination Deficiency (HRD) Assays in Patients with High-Grade Epithelial Ovarian Cancer. Cancers, 15(23), 5525. https://doi.org/10.3390/cancers15235525

Vancouver

Fountzilas E, Papadopoulou K, Chatzikonstantinou T, Karakatsoulis G, Constantoulakis P, Tsantikidi A, et al. Concordance between Three Homologous Recombination Deficiency (HRD) Assays in Patients with High-Grade Epithelial Ovarian Cancer. Cancers. 2023;15(23):5525. doi:10.3390/cancers15235525

BibTeX
@article{Fountzilas2023,
  author = {Fountzilas, Elena and Papadopoulou, Kyriaki and Chatzikonstantinou, Thomas and Karakatsoulis, Georgios and Constantoulakis, Pantelis and Tsantikidi, Aikaterini and Tsaousis, Georgios and Karageorgopoulou, Sofia and Koumarianou, Anna and Mauri, Davide and Ntavatzikos, Anastasios and Saridaki, Zacharenia and Petrakis, Georgios and Fostira, Florentia and Fountzilas, George and Liontos, Michalis},
  title = {Concordance between Three Homologous Recombination Deficiency (HRD) Assays in Patients with High-Grade Epithelial Ovarian Cancer},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {23},
  pages = {5525},
  doi = {10.3390/cancers15235525}
}
Kostenlos starten →